Samsung Life Insurance (A032830) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jan, 2026Executive summary
Achieved record consolidated net profit of KRW 2.1 trillion in 2024, up 11.2% year-on-year, driven by strong health product sales, insurance, and investment gains.
New business CSM exceeded annual target, reaching KRW 3.3 trillion, with health products comprising 58% of new business CSM.
Maintained industry-leading exclusive FC channel, adding over 5,500 agents, totaling over 37,000 agents.
Dividend per share increased 21.6% to KRW 4,500, with total dividends at KRW 808 billion, targeting a midterm payout ratio of 50%.
K-ICS ratio expected at 180% as of Dec 2024, maintaining sufficient capital despite regulatory tightening.
Financial highlights
CSM balance rose by KRW 0.7 trillion to KRW 12.9 trillion, a 5.3% increase year-on-year.
Investment yield reached 3.09% through asset diversification; invested assets totaled KRW 214 trillion.
Shareholders' equity at KRW 32.7 trillion, down KRW 11.6 trillion year-on-year due to regulatory changes and lower Samsung Electronics share price.
Insurance service results contributed KRW 542 billion; investment profit totaled KRW 2,272 billion.
Protection persistency ratio at 90% (13th month) and 69% (25th month), maintaining high industry standards.
Outlook and guidance
Plans to further expand health product mix to 70% of new business CSM in 2025.
Targeting insurance profit above KRW 1 trillion for 2025, with continued focus on high-quality new business and efficiency improvements.
Aims to maintain K-ICS ratio at low-to-mid 180% in 2024, with a minimum target of 150% under stress scenarios.
FY25 strategy focuses on expanding high-margin health insurance, digital competitiveness, and overseas business.
Mid-term shareholder return policy aims for a 50% payout ratio within the next three to four years.
Latest events from Samsung Life Insurance
- Net profit up 40.5% to KRW 1.37T in H1 2024; health CSM leads; 50% payout ratio targeted.A032830
Q2 20248 Jul 2026 - Q1 2025 net profit reached KRW 677.5B, assets KRW 318.9T, solvency margin 218.8%.A032830
Q1 20258 Jul 2026 - H1 2025 net profit up 1.9% to KRW 1.394T, KICS at 187%, assets KRW 319.1T, ESG AA.A032830
Q2 202524 Jun 2026 - Q3 net profit up 41.6% YoY, strong health insurance and capital, CSM at ₩13 trillion.A032830
Q3 202424 Jun 2026 - Net profit up 3.7% YoY, with strong capital, health CSM growth, and higher equity.A032830
Q3 202524 Jun 2026 - Q1 net income up 89.5%–90% YoY, CSM and health product sales surged, K-ICS ratio at 210%.A032830
Q1 202621 May 2026 - FY2025 net profit rose 9.3% to KRW 2.3T, with record CSM and DPS up 18%; strong 2026 growth targeted.A032830
Q4 202512 Apr 2026